Evaluation of the clinical and radiographic effectiveness of treating peri-implant bone defects with a new biphasic calcium phosphate bone graft: a prospective, multicenter randomized controlled trial
Jae‐Hong Lee, Hyun‐Wook An, Jae-Seung Im, Woo-Joo Kim, Dong‐Won Lee, Jeong‐Ho Yun
Abstract
PURPOSE: Biphasic calcium phosphate (BCP), a widely used biomaterial for bone regeneration, contains synthetic hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP), the ratio of which can be adjusted to modulate the rate of degradation. The aim of this study was to evaluate the clinical and radiographic benefits of reconstructing peri-implant bone defects with a newly developed BCP consisting of 40% β-TCP and 60% HA compared to demineralized bovine bone mineral (DBBM). METHODS: -test and the χ² test. RESULTS: =0.133), postoperative discomfort, or early wound healing. No adverse or fatal complications occurred in either group. CONCLUSION: The GBR procedure with the newly developed BCP showed favorable clinical, radiographic, postoperative discomfort-related, and early wound healing outcomes for peri-implant dehiscence defects that were similar to those for DBBM. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0006428.